Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.72 -7.5%	$0.99	$0.51 ▼ $1.89	$95.57M	-0.2	66,703 shs	262,179 shs
MRSN Mersana Therapeutics	$0.35 -2.9%	$0.35	$0.26 ▼ $2.83	$43.97M	0.79	2.78 million shs	1.49 million shs
NXTC NextCure	$4.99 -2.7%	$5.67	$2.69 ▼ $21.48	$13.35M	1.06	11,618 shs	29,253 shs
SPRO Spero Therapeutics	$2.37 -4.4%	$2.26	$0.51 ▼ $3.22	$132.51M	1.33	1.24 million shs	969,965 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	+13.16%	+71.98%	+132.68%	+33.33%
MRSN Mersana Therapeutics	0.00%	+2.59%	-0.93%	-0.54%	-83.67%
NXTC NextCure	0.00%	+5.27%	-8.12%	+15.13%	-76.37%
SPRO Spero Therapeutics	0.00%	-15.66%	-19.39%	+214.24%	+60.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	2.6105 of 5 stars	3.5	3.0	0.0	2.3	2.5	0.0
MRSN Mersana Therapeutics	3.7311 of 5 stars	3.5	3.0	4.1	0.0	2.5	0.0
NXTC NextCure	4.2354 of 5 stars	3.4	3.0	4.3	1.5	1.7	1.3
SPRO Spero Therapeutics	3.4432 of 5 stars	3.3	3.0	4.7	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.00	Buy	$7.00	306.98% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,373.92% Upside
NXTC NextCure	2.75	Moderate Buy	$33.00	561.32% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	110.97% Upside

Current Analyst Ratings Breakdown

Latest NXTC, CNTB, MRSN, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$26.03M	3.67	N/A	N/A	$1.67 per share	1.03
MRSN Mersana Therapeutics	$40.50M	1.09	N/A	N/A	($0.08) per share	-4.41
NXTC NextCure	N/A	N/A	N/A	N/A	$28.06 per share	N/A
SPRO Spero Therapeutics	$47.98M	2.76	N/A	N/A	$0.85 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
NXTC NextCure	-$55.65M	-$21.13	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest NXTC, CNTB, MRSN, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$0.39	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	SPRO Spero Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/1/2025	Q1 2025	NXTC NextCure	-$4.80	-$4.68	+$0.12	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	10.25	10.25
MRSN Mersana Therapeutics	N/A	1.83	1.83
NXTC NextCure	N/A	10.26	10.26
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
MRSN Mersana Therapeutics	93.92%
NXTC NextCure	42.65%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
MRSN Mersana Therapeutics	13.00%
NXTC NextCure	17.90%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

NXTC, CNTB, MRSN, and SPRO Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?

July 1, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street Zen

June 21, 2025 | marketbeat.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 29, 2025 | finanznachrichten.de

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, CNTB, MRSN, and SPRO Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.72 -0.14 (-7.53%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.68 -0.03 (-2.03%)

As of 07/18/2025 07:36 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Mersana Therapeutics NASDAQ:MRSN

$0.35 -0.01 (-2.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.35 0.00 (-0.23%)

As of 07/18/2025 07:49 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

NextCure NASDAQ:NXTC

$4.99 -0.14 (-2.73%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.05 +0.06 (+1.20%)

As of 07/18/2025 07:16 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Spero Therapeutics NASDAQ:SPRO

$2.37 -0.11 (-4.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.34 -0.03 (-1.43%)

As of 07/18/2025 07:50 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time